Pfizer (PFE)
$28.05
0.35 (1.26%)
PFE Stock Quote Delayed 30 Minutes
Here’s Why Pfizer Inc. Stock Is a Great Tax Plan Play
PFE just got some great news in the Republican tax plan. News that will continue to pad Pfizer's dividend potential for years to come.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
157.27B
PE Ratio
-561.00
EPS
-0.05
Volume (Avg. Vol.)
17.27M
Day's Range
$27.67 - $28.09
52-Week Range
$25.20 - $37.80
Dividend & Yield
$1.64 (5.85%)
PFE Stock Predictions, Articles, and Pfizer News
Improving Earnings Growth Analytics Drive Upgrade of Pfizer (PFE) to Buy
Pfizer Inc (NYSE:PFE) is one of 133 companies within the Pharmaceuticals GICS industry group, which is in turn part of the 781 company GICS Health Care sector. PFE has a market value of $210.8 billion which is in the top 10% of its industry group. The ranking for PFE by Portfolio Grader places it 35 among the 133 companies in this industry group, placing it in the top half; in the top half of the sector with a ranking of 206 among the 781 companies in the sector, and number 1,335 in the nearly 5,000 company Portfolio Grader universe.
Pfizer (PFE) a Hold on Pallid Sales Growth
Pfizer Inc (NYSE:PFE) is a $209.7 billion in market value component of the Pharmaceuticals GICS industry group where the ranking for PFE by Portfolio Grader places it 44 among the 132 companies in this industry group, placing it in the top half. PFE is ranked in the top half of the sector with a ranking of 286 among the 782 companies in the sector and number 1,779 in the 5000 company Portfolio Grader company universe.
Why It’s Time to Put Pfizer Inc. Stock on Your Watchlist
Pfizer may not be a great company now, but it may be a great company again soon. Time to put PFE stock on your watchlist.
How to Know if You Should Buy, Sell or Hold Pfizer Inc.
Pfizer Inc didn’t lap the field in its latest earnings. Nonetheless, PFE stock is still a worthy candidate for your portfolio.
Pfizer (PFE) Quant Score Hurt Rating
Pfizer Inc (NYSE:PFE) is classified as a member of the 133 company Pharmaceuticals GICS industry group, which is a segment of the 785 company GICS Health Care sector. PFE's market value is $211.4 billion which falls in the top 10% of its industry group. The ranking for PFE by Portfolio Grader places it 54 among the 133 companies in this industry group, placing it in the top half; in the top half of the sector with a ranking of 341 among the 785 companies in the sector, and number 2,194 in the nearly 5,000 company Portfolio Grader universe.
Go Long Mylan N.V. After Earnings With Confidence
Biotech companies are still under threat from the White House. So I sell risk in Mylan for income into those fears. Bet on MYL stock support for cash.
Pfizer (PFE) Sales Growth Hurts Rating
With a $211.7 billion market value, Pfizer Inc (NYSE:PFE) ranks in the top 10% of its industry group, Pharmaceuticals, and in the top 10% of its sector group, Health Care, in market value. From the viewpoint of investment attractiveness, Portfolio Grader's current ranking for PFE puts it 61 among the 133 companies in this industry group, giving it an above-average position; in the third quartile of the sector with a ranking of 407 among the 783 companies in the sector, and number 2,739 in the nearly 5,000 company Portfolio Grader universe.
Pfizer Inc. May Be About to Turn the Corner With Likely Consumer Unit Sale
Pfizer reported lousy third-quarter earnings, but that doesn’t mean PFE stock is priced for such blah results.
Pfizer Inc. Stock Earnings Were a Snooze — But That’s Good
PFE stock has been lagging the broad market for a few years now, but that lack of volatility from Pfizer stock is working out well for the time being.
Pfizer Inc. Stock Is Boring, and That’s Perfect
Pfizer has been a boring stock for years. Which makes PFE stock perfect to sell downside risk against unlikely scenarios.
Anemic Industry Group Rank Hurts Pfizer (PFE) Rating
Currently, Pfizer Inc (NYSE:PFE) has a Hold using the approach to investing of Louis Navellier and his Portfolio Grader stock evaluator. PFE has recently seen its Portfolio Grader rating upgraded from a Sell to a Hold.
Buy the Dip in Amgen, Inc. While Wall Street Fears It
Biotech falling knives like Amgen are notoriously dangerous, but AMGN stock has value against which I am willing to bet bullish.
Quant Score Analytics Limit Pfizer (PFE) Upgrade to Hold
Currently, Pfizer Inc (NYSE:PFE) has a Hold using Louis Navellier's investing methodology and his Portfolio Grader stock evaluator. PFE has been upgraded from a Sell to a Hold in the last week.
Dow Jones Industrial Average Hits 23,000. Now What?
The Dow Jones Industrial Average is definitely overbought. I wouldn't be a buyer, but staying long could have its advantages.
Pfizer Inc. (PFE) May Spin Off Consumer Health Biz
Pfizer (PFE) is reportedly considering spinning off its consumer health brands. The combination of these brands is worth about $15 billion.
